Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR | Market Cap | 13.66B +23.5% |
| Revenue (ttm) | 6.52B +9.1% |
| Net Income | 878.34M -1.7% |
| EPS | 43.85 -1.7% |
| Shares Out | 20.03M |
| PE Ratio | 15.56 |
| Forward PE | n/a |
| Dividend | 1.80 (0.26%) |
| Ex-Dividend Date | Sep 12, 2025 |
| Volume | 10,408 |
| Average Volume | 11,044 |
| Open | 641.00 |
| Previous Close | 641.25 |
| Day's Range | 637.00 - 684.70 |
| 52-Week Range | 439.95 - 731.50 |
| Beta | 0.40 |
| RSI | 66.47 |
| Earnings Date | May 21, 2026 |
About Lincoln Pharmaceuticals
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As... [Read more]
Financial Performance
In fiscal year 2025, Lincoln Pharmaceuticals's revenue was 6.23 billion, an increase of 7.35% compared to the previous year's 5.81 billion. Earnings were 823.46 million, a decrease of -11.74%.
Financial StatementsNews
Lincoln Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw strong revenue and profit growth, with exports and new product launches driving performance. Management maintains a 15%-18% EBITDA margin outlook and targets INR 1,000 crore revenue by FY28, supported by expansion in regulated markets and ongoing R&D investments.
Lincoln Pharmaceuticals successfully completes trial run at new API facility in Gujarat
Lincoln Pharmaceuticals has announced the successful completion of the trial run at its new manufacturing facility located at Trimul Estate, Khatraj, in Gandhinagar district, Gujarat. This state-of-th...